In the last trading session, 1.92 million Tenaya Therapeutics Inc (NASDAQ:TNYA) shares changed hands as the company’s beta touched 2.90. With the company’s per share price at $1.46 changed hands at $0.04 or 2.82% during last session, the market valuation stood at $115.66M. TNYA’s last price was a discount, traded about -380.14% off its 52-week high of $7.01. The share price had its 52-week low at $0.99, which suggests the last value was 32.19% up since then. When we look at Tenaya Therapeutics Inc’s average trading volume, we note the 10-day average is 2.83 million shares, with the 3-month average coming to 4.82 million.
Analysts gave the Tenaya Therapeutics Inc (TNYA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TNYA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Tenaya Therapeutics Inc’s EPS for the current quarter is expected to be -0.31.
Tenaya Therapeutics Inc (NASDAQ:TNYA) trade information
Instantly TNYA was in green as seen at the end of in last trading. With action 2.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 2.10%, with the 5-day performance at 2.82% in the green. However, in the 30-day time frame, Tenaya Therapeutics Inc (NASDAQ:TNYA) is -61.38% down. Looking at the short shares, we see there were 16.69 million shares sold at short interest cover period of 3.42 days.
Tenaya Therapeutics Inc (TNYA) estimates and forecasts
Data shows that the Tenaya Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -58.29% over the past 6 months, a 19.64% in annual growth rate that is considerably higher than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -27.43%. The 2025 estimates are for Tenaya Therapeutics Inc earnings to increase by 19.60%.
TNYA Dividends
Tenaya Therapeutics Inc is expected to release its next quarterly earnings report in February.
Tenaya Therapeutics Inc (NASDAQ:TNYA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.17% of Tenaya Therapeutics Inc shares while 73.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 74.68%. There are 73.81% institutions holding the Tenaya Therapeutics Inc stock share, with COLUMN GROUP LLC the top institutional holder. As of 2024-06-30, the company held 11.6078% of the shares, roughly 9.4 million TNYA shares worth $29.14 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 9.4124% or 7.62 million shares worth $23.63 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . With 2.1 shares estimated at $3.06 million under it, the former controlled 2.65% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.61% of the shares, roughly 2.06 shares worth around $3.01 million.
